Ipsen S.A.
IPNPharmaceuticals
€155.80+1.90%As of Oct 29vs prior close
- Market cap
- $14.3B
- P/E (TTM)
- 25.1×
- P/E (FY1)
- 9.5×
- From 52W high
- −8.94%
- EPS (LTM)
- €6.18
- Revenue (LTM)
- €4.3B
- Net margin
- 11.95%
- Dividend yield
- 1.03%
Nomior Score
65
Steady ProfileTop 18% of the scored universe
Growth46
Quality64
Value60
Momentum65
Resilience61
Growth
+7.57%revenue a year over 3 fiscal years
YE22 €3.2BLTM €4.3B
Connections
Revenue to profitYE25
11% of revenue became net profit, up 2 pts on a year.